Barclays initiated coverage on Oscar Health with a new price target
$OSCR
Medical Specialities
Health Care
Barclays initiated coverage of Oscar Health with a rating of Underweight and set a new price target of $17.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2025 | $14.00 | Outperform → Neutral | Robert W. Baird |
| 7/15/2025 | $11.00 | Neutral → Sell | UBS |
| 7/14/2025 | $14.00 | Overweight → Neutral | Piper Sandler |
| 7/11/2025 | $10.00 | Equal Weight → Underweight | Wells Fargo |
| 7/2/2025 | $17.00 | Underweight | Barclays |
| 6/24/2025 | Outperform → Mkt Perform | Raymond James | |
| 3/13/2025 | $20.00 → $16.00 | Overweight → Equal Weight | Wells Fargo |
| 12/10/2024 | $12.00 | Underperform | Jefferies |
Oscar Health, Inc. (NYSE:OSCR), a leading healthcare technology company in the individual market, and Hy-Vee, Inc., America's No. 1 grocery store based in the Midwest, are teaming up to introduce a one-of-a-kind healthcare benefit. The landmark health insurance plan saves employers money and gives employees concierge care at an affordable fixed price. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813844103/en/ Hy-Vee Health with Oscar* is powered by two industry-leading brands. Together they set a new standard: healthcare made simple. Hy-Vee brings more than 270 retail pharmacies, nearly 300 grocery stores, and concierge pri
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the second quarter ended June 30, 2025, and reaffirmed its updated full year 2025 outlook across all metrics as provided in its preliminary financial results press release dated July 22, 2025. "We believe the individual market has long-term upside and is the future of healthcare," said Mark Bertolini, CEO of Oscar Health. "Oscar is well-positioned to manage through the market reset in 2025. We believe the market will stabilize next year, and expect to return to profitability in 2026. We are building the individual market into a healthcare marketplace for more consumers and businesses, and c
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today certain preliminary financial results for the second quarter ended June 30, 2025 and updates to full year 2025 guidance. The Company expects a loss from operations of approximately $230 million and a net loss of approximately $228 million for the second quarter of 2025. The preannouncement is driven by a review of 2025 Marketplace data ("2Q Risk Adjustment Reports") from Wakely, an independent actuarial firm, that analyzes paid claims submissions through April 30, 2025 for most Marketplace insurance carriers. "The individual market is a competitive healthcare marketplace tha
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
10-Q - Oscar Health, Inc. (0001568651) (Filer)
8-K - Oscar Health, Inc. (0001568651) (Filer)
SCHEDULE 13G/A - Oscar Health, Inc. (0001568651) (Subject)
Robert W. Baird downgraded Oscar Health from Outperform to Neutral and set a new price target of $14.00
UBS downgraded Oscar Health from Neutral to Sell and set a new price target of $11.00
Piper Sandler downgraded Oscar Health from Overweight to Neutral and set a new price target of $14.00
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)
SC 13G - Oscar Health, Inc. (0001568651) (Subject)
SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the second quarter ended June 30, 2025, and reaffirmed its updated full year 2025 outlook across all metrics as provided in its preliminary financial results press release dated July 22, 2025. "We believe the individual market has long-term upside and is the future of healthcare," said Mark Bertolini, CEO of Oscar Health. "Oscar is well-positioned to manage through the market reset in 2025. We believe the market will stabilize next year, and expect to return to profitability in 2026. We are building the individual market into a healthcare marketplace for more consumers and businesses, and c
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today certain preliminary financial results for the second quarter ended June 30, 2025 and updates to full year 2025 guidance. The Company expects a loss from operations of approximately $230 million and a net loss of approximately $228 million for the second quarter of 2025. The preannouncement is driven by a review of 2025 Marketplace data ("2Q Risk Adjustment Reports") from Wakely, an independent actuarial firm, that analyzes paid claims submissions through April 30, 2025 for most Marketplace insurance carriers. "The individual market is a competitive healthcare marketplace tha
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us